DENMARK —Danish dermatology specialist, LEO Pharma, has announced a strategic partnership with the Irish firm, ICON, to focus on clinical trial execution.
With a significant presence in the dermatology products market, LEO Pharma’s partnership with ICON is expected to facilitate the scaling up of clinical trial operations, in a patient-centric and cost-effective manner.
This alliance aims to create one of the most efficient and effective clinical portfolio execution organizations in the industry.
As the demand for dermatology products continues to grow worldwide, this collaboration will allow LEO Pharma to streamline its clinical trial process and expedite the development of innovative therapies, which can potentially cater to a broader patient population.
In the highly competitive dermatology space, LEO Pharma has positioned itself as a leading player, with a strong focus on developing innovative therapies to address the unmet needs of patients.
With decades of research and development in dermatology, LEO Pharma has built a robust portfolio of therapies for various disease severities, ranging from mild to severe.
Some of the company’s most notable products include Enstilar, a treatment for psoriasis, and Kyntheum, a biologic therapy for moderate-to-severe psoriasis.
In addition to its existing product offerings, LEO Pharma continues to invest heavily in research and development, with a pipeline of promising therapies in various stages of development.
The company’s focus on dermatology has allowed it to establish a strong brand presence in the market and earn the trust of healthcare professionals and patients worldwide.
However, LEO Pharma faces fierce competition from other major players in the dermatology space, such as AbbVie, Johnson & Johnson, Novartis, and Pfizer.
These companies also have significant expertise and resources to develop and market dermatology products globally.
Meanwhile, Leo Pharma’s delgocitinib cream met primary and secondary endpoints in a late-stage trial for moderate to severe chronic hand eczema, showing a statistically significant improvement in eczema clearing and relief from itch and pain scores.
The company aims to evaluate the drug’s long-term effects in a third phase 3 trial. Delgocitinib won approval in Japan in 2020 to treat atopic dermatitis and received pediatric approval a year later.
The drug competes with Incyte’s Opzelura, the only FDA-approved JAK inhibitor cream for atopic dermatitis and nonsegmental vitiligo.
JAK inhibitors have raised safety concerns and carry boxed warnings. Opzelura’s warning includes risks of serious infections, cancer, heart-related events, blood clots, and death.
Despite this, key opinion leaders are less worried about the safety of topical JAK medications, according to a GlobalData survey.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
